



The last day of trading with the warrants of series TO3 in Alzinova AB is today, April 21, 2023

Today, April 21, 2023, is the last day of trading with the warrants of series TO3 (“Warrants”) in Alzinova AB (“Alzinova” or the “Company”). The exercise period for the Warrants runs up to and including April 25, 2023. Each Warrant gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the Warrants is SEK 2.17 per share.

If all the Warrants are exercised, the Company will receive approximately SEK 28.1 million before issuing costs. In order to prevent the Warrants expiring without value, the holder must actively subscribe for new shares, no later than April 25, 2023. Alternatively, the holder may sell the Warrants, no later than today, April 21, 2023. Please be aware that certain nominees may close their application earlier than April 25, 2023. Complete terms and conditions for the Warrants are available at the Company’s website for the Warrants, www.to3.alzinova.com.

Summarized terms for the Warrants:

Exercise period: April 11, 2023 – April 25, 2023.

Subscription price: SEK 2.17 per share.

Issue volume: 12,967,612 Warrants. If all the Warrants are exercised, 12,967,612 shares are issued, and the Company will receive approximately SEK 28.1 million before issuing costs.

Last day for trading with Warrants: April 21, 2023.

Share capital and dilution: If all Warrants are exercised the share capital will increase with SEK 3,410,481.956, from SEK 8,526,205.942 to SEK 11,936,687.898. The number of shares will increase with 12,967,612 shares if all Warrants are exercised, from 32,419,034 shares to 45,386,646 shares. The dilution at full exercise of all Warrants amounts to approximately 28.6 percent of the number of shares and votes in the Company.

Note that the Warrants that are not exercised at the latest April 25, 2023, or sold at the latest April 21, 2023, will expire without value. For the Warrants not to lose their value, the holder must actively subscribe for new shares or sell the Warrants. Please observe that some nominees may close their registration earlier than April 25, 2023.

How the Warrants are exercised:



Nominee-registered warrants (custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The Warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Instructions for subscription are available at Alzinova's website for the Warrants, www.to3.alzinova.com and on Mangold Fondkommission AB's website, www.mangold.se.

Advisers

Mangold Fondkommission AB is the financial adviser, Fredersen Advokatbyrå AB is the legal adviser and Shark Communication is the communication adviser to the Company in connection with the exercise of the Warrants.

For questions regarding the Warrants, please contact:

Mangold Fondkommission AB
E-mail: emissioner@mangold.se

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com



Attachments

The last day of trading with the warrants of series TO3 in Alzinova AB is today, April 21, 2023